|
Tamiflu
General, Technology,
Production, Manufacturing Process, Marketing, Suppliers, Distributors
Primary Information Services
Home.
Ordering Information.
Contact
|
General
- Tamiflu is an antiviral medicine to
treat infection caused by influenza virus. Tamiflu does not prevent you
from getting the flu. Tamiflu is used to treat seasonal or annual flu
viruses.
- Tamiflu belongs to a group of
medicines called neuraminidase inhibitors.
-
Tamiflu (oseltamivir phosphate) is available as a
capsule containing 75-mg oseltamivir for oral use, in the form of
oseltamivir phosphate.
-
Tamiflu is indicated for the treatment of uncomplicated
acute illness due to influenza infection in adults who have been
symptomatic for no more than 2 days.
Technology
-
Naturally acquired and experimental influenza, treatment
with Tamiflu did not impair normal humoral antibody response to infection.
-
Antiviral activity of Tamiflu was supported for influenza
A and B by experimental challenge studies in volunteers who received
intranasal inoculations of challenge strains of influenza virus.
-
Research capacity and many years of experience in drug
development are clearly reflected in its success on the preparation of key
components for Tamiflu and Relenza
-
Tamiflu is a flu treatment; it is not a flu
vaccine. Though it has been demonstrated to be moderately effective
against Avian Flu in laboratory experiments, it is only effective when
taken within two days of flu symptoms appearing.
Applications
-
Tamiflu is used to treat or prevent influenza in adults
and children over the age of one
-
In the treatment of flu, it can be used in patients who
have the symptoms of flu, when the influenza virus is known to circulate
in the community..
-
In the prevention of flu, Tamiflu must be started within
two days of the contact with someone who has flu.
-
Tamiflu is given as one dose once a day for at least 10
days after contact with an infected person. When Tamiflu is used during a
flu epidemic, this dose can be given for up to 6 weeks. The doses need to
be lower in patients who have kidney problems.
Market
- Roche announces today that it will
have increased its own production capacity to produce 300 million
treatments of Tamiflu annually. The expansion will be achieved by a
further stepwise scale-up of Roche’s production network
-
The U.S. federal government reportedly has ordered 5.3
million courses of Tamiflu for the Strategic National Stockpile, however
it would require approximately 70 million courses to cover 25 percent of
the U.S. population.
Report
-
Tamiflu contains the active substance oseltamivir. Tamiflu
is presented as grey and yellow hard capsules for oral use or as a powder
to make up an oral suspension.
-
The effects of Tamiflu were first tested in experimental
models before being studied in humans. In humans, Tamiflu has been
compared to placebo in studies in the treatment of flu the effectiveness
was measured using a score card where patients recorded their symptoms.
-
The Committee for Medicinal Products for Human Use (CHMP)
decided that Tamiflu’s benefits are greater than its risks for the
treatment and prevention of influenza, as an additional method in case of
a pandemic or when the flu vaccines are not effective against the
influenza virus causing the seasonal epidemic.
Entrepreneur who want
the informations on "General,
Technology, Production, Manufacturing Process, Marketing, Suppliers,
Distributors "
can
Order the CD ROM Today
|
|
Primary
Information Services
21 Murugappan St, SwamyNagar
Ext2,
Ullagaram, Chennai - 600091, India.
Phone:
91 44 22421080 Email :
informer@eth.net
Mobile
numbers:9940043898, 9444008898 Fax : 91 44
22423753 |